** Shares of Neurizon Therapeutics NUZ.AX rise as much as 3.2% to A$0.160, their biggest intraday pct gain since June 26
** The biotechnology co enters into a global licensing agreement with Elanco Animal Health ELAN.N
** Agreement is for exclusive rights to Elanco's data package and related intellectual property for Monepantel, the active pharmaceutical ingredient in co's NUZ-001, a formulation used in neurodegeneration applications
** YTD, shares of co down 5.9%
(Reporting by Nichiket Sunil in Bengaluru)
((Nichiket.Sunil@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.